Niagen Bioscience CEO Robert Fried discusses the science of NAD, the problems with the supplement industry, and how his company is leading the way in anti-aging research.

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Executives from Niagen Bioscience, Pushly, and VidaCorp discuss brand evolution. Learn why authenticity, community, and AI are key to building a resilient brand.

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

View the latest Niagen Bioscience Inc. (NAGE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

This initiative is part of the brand’s commitment to providing guests with science-backed health and wellness services.

Niagen Bioscience, Inc., the global authority on NAD+ with a focus on the science of healthy aging, today announced the continued expansion of its clinical footprint with additional new clinics ...

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, ...

Niagen Bioscience (NASDAQ:NAGE) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.

Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-405-5227 [email protected]. Niagen Bioscience Investor Relations Contact: ...